Item 7.01 Regulation FD Disclosure.

On January 9, 2023, C4 Therapeutics, Inc. (the "Company") issued a press release announcing its key milestones for 2023. A copy of the press release is furnished herewith as Exhibit 99.1.

Further, on January 9, 2023, the Company posted an investor presentation to its website at https://ir.c4therapeutics.com/events-presentations. A copy of the investor presentation is furnished herewith as Exhibit 99.2.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.



   Exhibit
   Number                                            Description
99.1                  Press release issued January 9, 2023
                      Investor presentation of the Company dated January 2023 (furnished
99.2                herewith)
104.0               Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses